Article
Medicine, General & Internal
David M. Nathan, GRADE Study Res Grp, John M. Lachin, Ashok Balsubramanyam, Henry B. Burch, John B. Buse, Nicole M. Butera, Robert M. Cohen, Jill P. Crandall, Steven E. Kahn, Heidi Krause-Steinrauf, Mary E. Larkin, Neda Rasouli, Margaret Tiktin, Deborah J. Wexler, Naji Younes
Summary: In this trial, all four glucose-lowering medications added to metformin were effective in reducing glycated hemoglobin levels. Glargine and liraglutide showed modestly superior efficacy in achieving and maintaining target glycated hemoglobin levels.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Yannis Simos, Konstantinos Spyrou, Michaela Patila, Niki Karouta, Haralambos Stamatis, Dimitrios Gournis, Evangelia Dounousi, Dimitrios Peschos
Summary: Current oral modalities for treating type 2 diabetes mellitus have drawbacks such as low bioavailability, immediate release of the drug necessitating increased dosing frequency, and potential adverse effects. Advances in nanotechnology offer the potential to improve drug bioavailability, prolong release, reduce dosing frequency, and enhance patient compliance and quality of life.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Article
Endocrinology & Metabolism
Ninna Hahn Tougaard, Alexandra Louise Moller, Pernille Falberg Ronn, Tine Willum Hansen, Federica Genovese, Morten Asser Karsdal, Daniel Guldager Kring Rasmussen, Peter Rossing
Summary: The study found that serum endotrophin is a risk marker for kidney and cardiovascular complications in type 2 diabetes, while urine endotrophin is a marker for albuminuria progression.
Article
Endocrinology & Metabolism
Beini Lyu, Yingying Sang, Elizabeth Selvin, Alex R. Chang, G. Caleb Alexander, Cheli Melzer Cohen, Josef Coresh, Varda Shalev, Gabriel Chodick, Avraham Karasik, Juan-Jesus Carrero, Edouard L. Fu, Yang Xu, Morgan E. Grams, Jung-Im Shin
Summary: There were substantial differences in real-world use of glucose-lowering medications across the U.S., Sweden, and Israel, with more optimal pharmacologic management in Israel. Variation in access to care and medication cost may have contributed to these differences. Use of SGLT2i and GLP1RA in high-risk patients was limited in all three countries during this time period.
Article
Plant Sciences
Jinni Meng, Yafei Zhu, Huixia Ma, Xiaobo Wang, Qipeng Zhao
Summary: Traditional Chinese medicine (TCM) has been shown to be effective and safe in treating diabetic cognitive dysfunction (DCD), mainly by improving insulin resistance, microvascular dysfunction, abnormal gut microbiota composition, and inflammation. More in vivo, in vitro, and clinical trials are needed to further understand the quality markers of TCM in DCD treatment.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Antonio Ceriello, Francesco Prattichizzo
Summary: Evidence suggests that diabetes is a significant comorbidity affecting the prognosis of COVID-19. Proper management of chronic anti-hypertensive and glucose-lowering therapies is crucial in treating diabetic patients with COVID-19. Careful balance of the body's response and effective medication management are essential for diabetic patients during COVID-19 treatment.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
(2021)
Review
Cell Biology
Jianxin Deng, Yunxiu Liao, Jianpin Liu, Wenjuan Liu, Dewen Yan
Summary: Diabetic cardiomyopathy is characterized by diastolic relaxation abnormalities in its early stages and clinical heart failure in its later stages, contributing to high mortality and morbidity rates in diabetic populations. Diabetes is a complex condition influenced by genetic and environmental factors, with recent studies highlighting the role of epigenetics in its pathogenesis. Further research on epigenetic mechanisms could lead to novel therapeutic approaches for diabetic cardiomyopathy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Nutrition & Dietetics
Naomi Niisato, Yoshinori Marunaka
Summary: Type 2 diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia and insufficient insulin secretion. Treatment mainly involves drug therapy, but long-term use of these drugs can have harmful side effects. Phytochemicals, particularly flavonoids, have shown promise in treating T2DM and reducing complications. Myricetin, a flavonoid, has multiple effects on T2DM targets, including inhibiting carbohydrate digestion, increasing insulin secretion, and protecting endothelial cells. This review compares the effects of myricetin with other flavonoids in T2DM treatment.
FRONTIERS IN NUTRITION
(2023)
Article
Clinical Neurology
Bang Zheng, Bowen Su, Sara Ahmadi-Abhari, Dimitrios Kapogiannis, Ioanna Tzoulaki, Elio Riboli, Lefkos Middleton
Summary: A study conducted in the UK found that type 2 diabetes patients who were treated with metformin had a lower risk of dementia. The risk was even lower for patients who used metformin for a longer duration.
ALZHEIMERS & DEMENTIA
(2023)
Review
Endocrinology & Metabolism
Karina Ramirez-Alarcon, Montserrat Victoriano, Lorena Mardones, Marcelo Villagran, Ahmed Al-Harrasi, Ahmed Al-Rawahi, Natalia Cruz-Martins, Javad Sharifi-Rad, Miquel Martorell
Summary: Prevalence of Type 2 diabetes Mellitus (T2DM) is on the rise globally due to factors such as aging populations, obesity, and sedentary lifestyles. Studies suggest that bioactive molecules in plants may have potential as epigenetic drugs for preventing and controlling T2DM, offering a promising alternative or complementary therapy to conventional hypoglycemic drugs with minimal side effects.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Biochemistry & Molecular Biology
W. Coles Keeter, Alina K. Moriarty, Elena Galkina
Summary: The development of cardiovascular diseases associated with Type-2 diabetes is a challenging public health burden in developed countries. Neutrophils play a critical role in the disease processes that contribute to the development of Type-2 diabetes and atherosclerosis.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2021)
Article
Endocrinology & Metabolism
Aaron J. J. Deutsch, Philip H. H. Schroeder, Ravi Mandla, Sarah Kang, Feyza Erenler, Josep M. M. Mercader, Miriam S. S. Udler, Jose C. C. Florez, Laura N. N. Brenner
Summary: The objective of this study was to assess the association between increased genetic risk of type 2 diabetes and the development of hyperglycemia after glucocorticoid treatment. The analysis found that individuals with higher genetic risk had a higher risk of glucocorticoid-induced hyperglycemia. This finding suggests the potential for risk stratification in precision medical treatment.
Article
Clinical Neurology
R. Nisha Aurora, Naresh M. Punjabi
Summary: The study found that in adults with type 2 diabetes, the severity of obstructive sleep apnea (OSA) is associated with postprandial hyperglycemia after dinner, but not after breakfast or lunch. This association was present in men but not in women.
Article
Endocrinology & Metabolism
Jung-Chi Li, Po-Chung Cheng, Chien-Nin Huang, Li-Fen Jian, Ying-Syuan Wu, Chih-Li Lin
Summary: This study investigates the effect of adding the antihypertensive drug Amlodipine to standard diabetes therapy on glycemic control in patients with type 2 diabetes mellitus (T2DM). The results show that patients who received additional Amlodipine demonstrated significantly improved glycemic control compared to those who received standard diabetes therapy after 24 weeks.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Pharmacology & Pharmacy
Chatzakis Christos, Cavoretto Paolo, Sotiriadis Alexandros
Summary: Gestational diabetes mellitus is a common medical complication of pregnancy, with several risk factors and interventions tested for prevention. Insulin administration is preferred for treating hyperglycemia in GDM, while metformin and glyburide are not regarded as first-line agents.
CURRENT PHARMACEUTICAL DESIGN
(2021)
Editorial Material
Medicine, Research & Experimental
Simeon I. Taylor, Bruce R. Leslie
JOURNAL OF CLINICAL INVESTIGATION
(2018)
Article
Endocrinology & Metabolism
Amber L. Beitelshees, Bruce R. Leslie, Simeon I. Taylor
Editorial Material
Endocrinology & Metabolism
Simeon I. Taylor, Richard D. DiMarchi
Correction
Genetics & Heredity
Amber L. Beitelshees, James M. Stevenson, Nihal El Rouby, Chrisly Dillon, Philip E. Empey, Elliot M. Fielstein, Julie A. Johnson, Nita A. Limdi, Henry H. Ong, Francesco Franchi, Dominick J. Angiolillo, Joshua F. Peterson, Marc B. Rosenman, Todd C. Skaar, Sony Tuteja, Larisa H. Cavallari
GENETICS IN MEDICINE
(2020)
Article
Genetics & Heredity
Amber L. Beitelshees, James M. Stevenson, Nihal El Rouby, Chrisly Dillon, Philip E. Empey, Elliot M. Fielstein, Julie A. Johnson, Nita A. Limdi, Henry H. Ong, Francesco Franchi, Dominick P. Angiolillo, Joshua F. Peterson, Marc B. Rosenman, Todd C. Skaar, Sony Tuteja, Larisa H. Cavallari
GENETICS IN MEDICINE
(2020)
Article
Pharmacology & Pharmacy
Benjamin Q. Duong, Meghan J. Arwood, J. Kevin Hicks, Amber L. Beitelshees, Francesco Franchi, John T. Houder, Nita A. Limdi, Kelsey J. Cook, Aniwaa Owusu Obeng, Natasha Petry, Sony Tuteja, Amanda R. Elsey, Larisa H. Cavallari, Kristin Wiisanen
PHARMACOGENOMICS & PERSONALIZED MEDICINE
(2020)
Editorial Material
Endocrinology & Metabolism
Simeon I. Taylor
Article
Cardiac & Cardiovascular Systems
Amber L. Beitelshees, Cameron D. Thomas, Philip E. Empey, George A. Stouffer, Dominick J. Angiolillo, Francesco Franchi, Sony Tuteja, Nita A. Limdi, James C. Lee, Julio D. Duarte, Rolf P. Kreutz, Todd C. Skaar, James C. Coons, Jay Giri, Caitrin W. McDonough, Rachel Rowland, James M. Stevenson, Thuy Thai, Mark R. Vesely, Jacob T. Wellen, Julie A. Johnson, Almut G. Winterstein, Larisa H. Cavallari, Craig R. Lee
Summary: The clinical implementation of CYP2C19-guided antiplatelet therapy after PCI has shown better outcomes compared to clopidogrel treatment. For patients with a CYP2C19 loss-of-function variant, alternative therapy significantly reduces the risk of major atherothrombotic events.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Editorial Material
Endocrinology & Metabolism
Scott J. Pilla, Zhinous Shahidzadeh Yazdi, Simeon I. Taylor
Article
Endocrinology & Metabolism
Simeon I. Taylor, May E. Montasser, Ashley H. Yuen, Hubert Fan, Zhinoosossadat Shahidzadeh Yazdi, Hilary B. Whitlatch, Braxton D. Mitchell, Alan R. Shuldiner, Ranganath Muniyappa, Elizabeth A. Streeten, Amber L. Beitelshees
Summary: This study aimed to identify genetic variants associated with the variability of drug responses to glucagon-like peptide-1 receptor agonists. The findings showed that these drugs increased insulin secretion and accelerated glucose metabolism in healthy volunteers. However, they had minimal effects on insulin sensitivity. These findings highlight the importance of personalized medicine in drug treatments.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Simeon I. Taylor, Hua-Ren Cherng, Zhinous Shahidzadeh Yazdi, May E. Montasser, Hilary B. Whitlatch, Braxton D. Mitchell, Alan R. Shuldiner, Elizabeth A. Streeten, Amber L. Beitelshees
Summary: This study confirmed the pharmacodynamic responses to SGLT2 inhibitors and their association with genetic variants. Canagliflozin (300 mg) was shown to cause acute changes in biomarkers such as plasma glucose, serum creatinine, and serum uric acid levels. Normalizing data relative to creatinine excretion will facilitate the inclusion of data from both males and females in future analyses.
DIABETES OBESITY & METABOLISM
(2023)
Letter
Endocrinology & Metabolism
Simeon I. Taylor
JOURNAL OF THE ENDOCRINE SOCIETY
(2020)
Article
Endocrinology & Metabolism
Jenny E. Blau, Sri Harsha Tella, Simeon I. Taylor, Kristina I. Rother
DIABETES-METABOLISM RESEARCH AND REVIEWS
(2017)